Anthony Defelice
Orthopaedic Trauma Pittsfield, MA Doctor of Osteopathy
NPI 1902831043 CMS profile 176588
24 Park Street, Pittsfield, MA 01201
General payments
$3,323
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Anthony Defelice of Pittsfield, MA is reported in the CMS Open Payments database as having received $3,323 across 25 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 30th percentile of Orthopaedic Trauma profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $182 | 3 | |
| 2024 | General | $1,909 | 8 | |
| 2023 | General | $1,134 | 11 | |
| 2019 | General | $97 | 3 |
Beside peers
- Anthony Defelice
- Orthopaedic Trauma median
- Middle half of Orthopaedic Trauma
- National median
In program year 2025, general payments to Anthony Defelice were reported at $182. Among 734 Orthopaedic Trauma profiles paid that year, the median was $1,227 and the middle half received between $259 and $7,433.
Show as a table
| Year | Anthony Defelice | Orthopaedic Trauma median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $97 | $1,475 | $264–$6,401 | $163 |
| 2020 | $0 | $596 | $120–$4,020 | $114 |
| 2021 | $0 | $919 | $171–$4,697 | $132 |
| 2022 | $0 | $1,547 | $272–$7,240 | $149 |
| 2023 | $1,134 | $1,330 | $247–$5,875 | $160 |
| 2024 | $1,909 | $1,288 | $277–$6,797 | $164 |
| 2025 | $182 | $1,227 | $259–$7,433 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 96 billing codesPaid by Medicare
$316,943
Medicare patients
875
Services billed
12,720
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 73% | |
| High blood pressure | 69% | |
| Diabetes | 26% | |
| Depression | 24% | |
| Ischemic heart disease | 23% | |
| Osteoporosis | 20% | |
| COPD | 18% | |
| Cancer | 16% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg J7318 | Office | 70 | 7,080 | $36,475 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 | Office | 284 | 1,653 | $8,847 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 38 | 294 | $223 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
25 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Orthopaedic Trauma in Massachusetts
Related records
Orthopaedic Trauma in Massachusetts
Practitioners in the same specialty and state, ranked by reported value.
All Orthopaedic Trauma
Everyone recorded under this specialty, nationwide.
Doctors in Massachusetts
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.